AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA ...

Buoyed by growth opportunities and the strengthening economy, 2024 turned out to be an interesting year for the United ...

Changing a cultural undertow is one of the hardest leadership challenges in any industry, and perhaps even more so in the ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The NHS is reported to be in line for a £30 billion ($40.7 billion) increase to its budget in the UK government's upcoming ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to ...